The Canada Genotyping Assay Market was valued at $807 Million in 2024 and projected to reach to $1436.7 Million by 2029, representing a compound annual growth rate of 12.2%. Canada's genotyping assay market is positioned for sustained growth through 2029, driven by increasing adoption of precision medicine across healthcare systems and growing patient demand for personalized treatment options.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's genotyping assay market reached $807.0 million in 2024 and is projected to grow to $1,436.7 million by 2029, demonstrating strong market expansion driven by healthcare modernization and genomic adoption.
Canadian healthcare institutions are increasingly integrating genotyping assays into clinical practice, supported by government funding for genomic research and personalized medicine initiatives across provinces.
Investment in Canadian genomic research centers and biotech hubs is accelerating, with major institutions leveraging genotyping assays for disease prevention, drug development, and population health studies.
Canadian regulatory bodies and provincial health systems are actively supporting genomic testing adoption, with increased funding for precision healthcare programs and integration into standard clinical protocols.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | PHARMACOGENOMICS (Application) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 13.8% from 2024 to 2029 |
| Largest Segment | REAGENTS & KITS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 19.44 (2024) |
| Revenue Forecast (Billions) | ~USD 37.1 (2029) |
| Segments Covered | Product & Service, Type, Technology, Application, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 133 | 183.2 | 200.9 | 221.5 | 245.7 | 274.1 | 307.5 | 346.8 | 11.5 |
| DIAGNOSTIC LABORATORIES | 162.6 | 178.4 | 197.1 | 218.9 | 244.6 | 274.7 | 310.4 | 352.6 | 12.3 |
| OTHER END USERS | 155.3 | 130.1 | 141.7 | 155.2 | 171 | 189.5 | 211.1 | 236.5 | 10.8 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 216.2 | 239.6 | 267.3 | 299.8 | 338.1 | 383.3 | 436.9 | 500.7 | 13.4 |
| TOTAL | 667 | 731.3 | 807 | 895.5 | 999.4 | 1121.6 | 1265.9 | 1436.7 | 12.2 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SEQUENOM,INC. | United States | Private Company | MaterniT21 PLUS and VisibiliT NIPT,MaterniT21 GENOME and microarray (NextView),HerediT carrier screening (CF, Ashkenazi, SMA, fragile X), |
| DECODE GENETICS | Iceland | Private Company | Target discovery and validation for Amgen pipeline,Large-scale genome sequencing and analytics services,Data access, licensing, and collaborative research programs, |
| TRANSGENOMIC, INC. | United States | Public Company | Oncology and pharmacogenomics clinical trial services,Clinical oncology testing services (patient diagnostics and monitoring),Multiplexed ICE COLD-PCR reagents and technology licensing, |
| IMMUCOR, INC. | United States | Private Company | Transfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines OE,Commercial Engines Services & MRO,Defense & Propulsion Technologies – Engines, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Array-based instruments and consumables, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health),PCR and enzymes (qPCR, dPCR, research PCR kits), |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Tools,Other / Services and Software, |
| MERCK KGAA | Germany | Public Company | Life Science (lab reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, immunology, fertility, rare diseases),Electronics (semiconductor materials, specialty gases, display and OLED materials), |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics and qPCR systems (Biomark X9 and related assays),Services, software, and other consumables, |
| REVVITY | United States | Public Company | Diagnostics instruments and automation (AutoDELFIA, GSP, EUROIMMUN, IDS-iSYS, EUROLabWorkstation),Diagnostics reagents, assays, and kits (prenatal, newborn, autoimmune, infectious disease, T-SPOT),Life science reagents and consumables (BioLegend, Dharmacon, NEXTFLEX, AlphaLISA portfolio), |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read instruments and consumables (Onso platform), |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | PromethION platforms and consumables,MinION and portable platforms,GridION and mid-throughput systems, |
Sequenom, Inc. is a private molecular diagnostics company founded in 1994 in the United States with 434 employees. The company specializes in genetic testing and analysis.
Decode Genetics is a private genomics and biotechnology company founded in 1996 in Iceland with 331 employees. The company conducts genetic research and develops diagnostics based on genomic data.
Transgenomic, Inc. is a public molecular diagnostics company founded in 1997 in the United States with 19 employees. The company develops genetic testing and analysis technologies.
Immucor, Inc. is a private blood bank and transfusion diagnostics company founded in 1982 in the United States with 1,125 employees. The company provides immunohematology and transfusion medicine solutions.
General Electric is a public multinational conglomerate founded in 1892 in the United States with 57,000 employees. The company operates across diverse industries including healthcare, energy, and industrial sectors.
Thermo Fisher Scientific Inc. is a public life sciences and diagnostics company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
Illumina, Inc. is a public genomics and sequencing company founded in 1998 in the United States with 8,625 employees. The company develops DNA sequencing and genetic analysis technologies.
Danaher Corporation is a public diversified conglomerate founded in 1969 in the United States with 59,000 employees. The company operates across life sciences, diagnostics, and environmental solutions.
Qiagen is a public molecular diagnostics and life sciences company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample preparation, assay, and sequencing technologies.
Eurofins Scientific is a public laboratory services and diagnostics company founded in 1987 in Luxembourg with 65,694 employees. The company operates a global network of laboratories providing testing and analysis services.
Agilent Technologies, Inc. is a public life sciences and diagnostics company founded in 1999 in the United States with 18,000 employees. The company manufactures analytical instruments and laboratory equipment.
Bio-Rad Laboratories, Inc. is a public life sciences and diagnostics company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures clinical diagnostics and life science research products.
Merck KGaA is a public pharmaceutical and life sciences company founded in 1668 in Germany with 59,077 employees. The company provides pharmaceuticals, chemicals, and laboratory solutions globally.
Standard Biotools is a public life sciences instrumentation company founded in 1999 in the United States with 387 employees. The company develops microfluidics and single-cell analysis technologies.
Revvity is a public life sciences and diagnostics company founded in 1937 in the United States with 11,000 employees. The company provides analytical instruments, reagents, and software solutions.
PacBio is a public genomics sequencing company founded in 2000 in the United States with 485 employees. The company develops long-read DNA sequencing technologies.
Oxford Nanopore Technologies PLC is a public genomics sequencing company founded in 2005 in the United Kingdom with 1,316 employees. The company develops portable DNA and RNA sequencing technologies.
Canada's genotyping assay market was valued at $807.0 million in 2024 and is expected to grow to $1,436.7 million by 2029.
Canada's genotyping assay market is projected to grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2029.
Key drivers include increasing adoption of precision medicine, government funding for genomic research, growing demand for personalized healthcare, and integration of genotyping assays into clinical practice across Canadian healthcare institutions.
Oncology, pharmacogenomics, and infectious disease diagnostics are among the leading applications driving genotyping assay adoption in Canada.
Canada's 12.2% CAGR is slightly below the global average of 13.8%, reflecting Canada's mature healthcare system and steady, sustainable market expansion driven by precision medicine initiatives.
The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the genotyping assay market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
F. Hoffmann-La Roche Ltd. (Switzerland) |
Marketing Manager |
|
Thermo Fisher Scientific, Inc. (US) |
Senior Product Manager |
|
QIAGEN N.V. (Netherlands) |
Marketing Manager |
Both top-down and bottom-up approaches were used to estimate and validate the home healthcare market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Genotyping is used to study the differences in the genetic makeup (specific genome variants) of cells, microorganisms, plants, animals, and individuals. These differences in genotypes are determined by studying individual DNA sequences using biological assays and comparing them with other reference sequences. This process has wide applications in the field of life sciences, including animal genetics, diagnostic research, & pharmacogenomics, agricultural biotechnology, and personalized medicine.
MarketsandMarkets offers the following customizations for this market report
Full forecast, segment splits, and company analysis for all Genotyping Assay Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report